Creato da XagenaMedicina il 15/10/2009

Xagena Medicina

Discussione di argomenti medico-farmacologici

Messaggi del 03/07/2014

Cancer News & Drugs

  • Afinitor
    Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have ...
  • Enobosarm
    A randomised, double-blind, placebo controlled phase IIB trial has shown that treatment with Enobosarm, a non-steroidal selective androgen receptor modulator ...
  • Vorinostat
    On 20 September 2010, orphan designation was granted by the European Commission for Vorinostat for the treatment of malignant mesothelioma.Malignant ...
  • Xofigo
    The FDA ( Food and Drug Administration ) has approved Xofigo ( Radium Ra 223 dichloride; Radium-223 ) to treat men with symptomatic late-stage ...
  • Zactima
    AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA ( Vandetanib ) 100mg in combination with chemotherapy ...
  • Ramucirumab
    The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer who have had disease progression after ...
  • Nivolumab
    Bristol-Myers Squibb has announced long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort ( n=129 ) of the expanded ...
  • Gefitinib
    High copy number of the epidermal growth factor receptor ( EGFR ) may be an effective predictor of Gefitinib ( Iressa ) efficacy in non–small-cell lung cancer.
  •  
     
     
    RSS (Really simple syndication) Feed Atom
     

    AREA PERSONALE

     

    ARCHIVIO MESSAGGI

     
     << Luglio 2014 >> 
     
    LuMaMeGiVeSaDo
     
      1 2 3 4 5 6
    7 8 9 10 11 12 13
    14 15 16 17 18 19 20
    21 22 23 24 25 26 27
    28 29 30 31      
     
     

    CERCA IN QUESTO BLOG

      Trova
     

    FACEBOOK

     
     

    FACEBOOK

     
     
    Citazioni nei Blog Amici: 54
     

    ULTIME VISITE AL BLOG

    a_solitary_manprefazione09Alfa_Beta416161m12ps12acer.250Desert.69XagenaMedicinatiberis1santiago.gamboadony686marabertowiltuocognatino1cassetta2ilmondodiisidejonas21
     

    CHI PUò SCRIVERE SUL BLOG

    Solo l'autore può pubblicare messaggi in questo Blog e tutti gli utenti registrati possono pubblicare commenti.
    I messaggi e i commenti sono moderati dall'autore del blog, verranno verificati e pubblicati a sua discrezione.
     
    RSS (Really simple syndication) Feed Atom
     
     
     
     

    © Italiaonline S.p.A. 2024Direzione e coordinamento di Libero Acquisition S.á r.l.P. IVA 03970540963